These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 6171666)

  • 1. Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside.
    Presant CA; Vietti TJ; Valeriote F; Coulter DM
    J Natl Cancer Inst; 1981 Dec; 67(6):1283-8. PubMed ID: 6171666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological characterization of a prolonged antileukemic effect of 5-azacytidine.
    Presant CA; Valeriote F; Vietti TJ
    Cancer Res; 1977 Feb; 37(2):376-81. PubMed ID: 64294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia.
    Momparler RL; Momparler LF; Samson J
    Leuk Res; 1984; 8(6):1043-9. PubMed ID: 6083417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined effect of cytosine arabinoside and thiopurines.
    Valeriote F; Vietti T; Edelstein M
    Cancer Treat Rep; 1976 Dec; 60(12):1925-34. PubMed ID: 1026347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine.
    Neil GL; Berger AE; Bhuyan BK; DeSante DC
    Cancer Res; 1976 Mar; 36(3):1114-20. PubMed ID: 56229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic effects of a combination of intermediate-dose cytosine arabinoside, adriamycin and vincristine in relapsed acute leukemia].
    Takahashi I; Yorimitsu S; Inagaki T; Sekito N; Hayashi N; Nishimura M; Aoyama S; Nakada H; Ohmoto E; Uchida K
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):485-9. PubMed ID: 3813576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia.
    Chabot GG; Momparler RL
    Cancer Treat Rep; 1984 Dec; 68(12):1483-7. PubMed ID: 6210142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro biochemical and cytotoxicity studies with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine in combination.
    Momparler RL; Goodman J; Karon M
    Cancer Res; 1975 Oct; 35(10):2853-7. PubMed ID: 50882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine.
    Momparler RL; Momparler LF
    Cancer Chemother Pharmacol; 1989; 25(1):51-4. PubMed ID: 2480188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI; Powell W
    Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial synchronization of L1210 cells by 5-fluorouracil and its use in drug combinations.
    Bhuyan BK; Blowers CL; Neil GL; Bono VH; Day KJ
    Cancer Res; 1977 Sep; 37(9):3204-8. PubMed ID: 560250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
    Burke PJ; Karp JE; Vaughan WP
    J Natl Cancer Inst; 1981 Sep; 67(3):529-38. PubMed ID: 6944525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
    Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM
    Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2'-deoxycytidine and beta-2'-deoxythioguanosine.
    Momparler RL; Momparler LF; Samson J
    Int J Cancer; 1982 Sep; 30(3):361-64. PubMed ID: 6182115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia.
    Chello PL; Sirotnak FM
    Cancer Treat Rep; 1981; 65(11-12):1049-53. PubMed ID: 7296551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
    Schwartz SA; Morgenstern B; Capizzi RL
    Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of both leukemic and normal cell population reduction following 5-azacytidine.
    Presant CA; Vietti T; Valeriote F
    Cancer Res; 1975 Aug; 35(8):1926-30. PubMed ID: 50128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
    Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
    Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate.
    Edelstein M; Vietti T; Valeriote F
    Cancer Res; 1975 Jun; 35(6):1555-8. PubMed ID: 1131822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.